Clinical trials: Best Disease
Pancreatic Cancer
Study of the Efficacy and Safety of Glufosfamide Compared With Best Supportive Care in Metastatic Pancreatic Cancer
The primary objectives of the study is to evaluate the effectiveness and safety of glufosfamide in subjects with pancreatic cancer who have been previously treated with gemcitabine as measured by overall survival compared with…
- Trial name
- NCT00099294
- Testing
- Glufosfamide
- Where
- 111 sites in United States, Argentina and 9 more
- Volunteers
- 300 people
- Sponsor
- Threshold Pharmaceuticals
Colorectal Cancer
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
The purpose of this study is to compare the efficacy and safety of TAS-102 versus placebo in patients with refractory metastatic colorectal cancer.
- Trial name
- RECOURSE (NCT01607957)
- Testing
- TAS-102
- Where
- 115 sites in United States, Australia and 11 more
- Volunteers
- 800 people
- Sponsor
- Taiho Oncology, Inc.
Chronic Lymphocytic Leukemia (CLL)
Study of Oral Venetoclax Tablets in Combination With Intravenous Obinutuzumab Injection to Assess Achievement of Best Response in Adult Participants With Chronic Lymphocytic Leukemia
Chronic Lymphoid Leukemia (CLL) is the most common type of leukemia (cancer of blood cells) in adults affecting men more so than women.
- Trial name
- FIRST (NCT04655261)
- Where
- 4 sites in Russia
- Volunteers
- 5 people
- Sponsor
- AbbVie
Graft-versus-host Disease (GVHD)
A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
The purpose of this study is to assess the efficacy of ruxolitinib against best available therapy in participants with steroid-refractory chronic graft-versus-host disease (SR cGvHD).
- Trial name
- NCT03112603
- Testing
- Ruxolitinib, Extracorporeal photopheresis (ECP), Low-dose methotrexate (MTX)
- Where
- 191 sites in United States, Australia and 29 more
- Volunteers
- 330 people
- Sponsor
- Incyte Corporation
Atrial Fibrillation
Volunteers to Investigate Best Results for Ablation and Novel Therapies for Atrial Fibrillation
VIBRANT-AF seeks to: Identify clinically relevant predictors of effectiveness and complications of AF ablation procedures in a prospective, US-based, multi-center, real-world longitudinal study Assess changes in modifiable…
- Trial name
- VIBRANT-AF (NCT05504356)
- Where
- United States
- Volunteers
- 1,125 people
- Sponsor
- University of California, San Francisco
Non-Small Cell Lung Cancer
A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments
The purpose of this study is to compare the overall survival of patients receiving E7080 + Best Supportive Care (BSC) with those receiving placebo + Best Supportive Care.
- Trial name
- NCT01529112
- Testing
- Lenvatinib, BSC
- Where
- 50 sites in United States, Belgium and 5 more
- Volunteers
- 135 people
- Sponsor
- Eisai Inc.
Myelofibrosis, High-Risk Cancer
Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis
The purpose of this research study is to see how effective hematopoietic stem cell transplantation (HCT) is compared to best available non-transplant therapies (BAT) in patients with high risk myelofibrosis.
- Conditions
- Myelofibrosis, High-Risk Cancer, Bone Marrow Cancer
- Trial name
- ALLO-BAT (NCT04217356)
- Testing
- Hematopoietic stem cell transplant, Ruxolitinib, Hydroxyurea
- Where
- 5 sites in Canada
- Volunteers
- 90 people
- Sponsor
- University Health Network, Toronto
Carcinoid Heart Disease, Carcinoid Syndrome
Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy
Randomised trial to assess progression of carcinoid heart disease in patients treated with Lutathera therapy compared to best supportive care.
- Conditions
- Carcinoid Heart Disease, Carcinoid Syndrome, Carcinoid Tumor
- Trial name
- CHARRT (NCT04039516)
- Testing
- Lutathera
- Volunteers
- 20 people
- Sponsor
- King's College Hospital NHS Trust
Respiratory Complication, Obstructive Sleep Apnea
Applying Best Clinical Practices to Patients at High Risk of Respiratory Complications
The purpose of this study is to: 1. Perform a retrospective analysis on data contained in the UCLA Perioperative Data Warehouse on the incidence of respiratory dysfunction in the post-operative care unit (PACU) before and after…
- Trial name
- NCT04263363
- Testing
- Sugammadex 100 MG/ML [Bridion]
- Where
- United States
- Volunteers
- 12,248 people
- Sponsor
- University of California, Los Angeles
Phimosis
The Best Dose of Esketamine for Day Surgery of Pediatric Circumcision Pediatric Circumcision
In recent years, daytime operation has been developed gradually in China. Circumcision in children is a common type of daytime operation.
- Trial name
- NCT04698434
- Testing
- Esketamine
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Yangzhou University
Myelofibrosis
Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial
This was an open label, randomized study comparing the efficacy and safety of randomized 2:1 Ruxolitinib tablets versus best-available therapy, as selected by the investigator.
- Trial name
- NCT00934544
- Testing
- Ruxolitinib, Best Available Therapy (BAT)
- Where
- 61 sites in Austria, Belgium and 7 more
- Volunteers
- 219 people
- Sponsor
- Novartis Pharmaceuticals
Osteoporosis
People With Osteoporosis Can Walk-BEST to Reduce Fall and Fracture Risk
The aim of the Walk BEST study is to provide evidence that it is feasible to implement the technology assisted gait- focused walking program Walk-BEST™ in older adults with osteoporosis, and that this program is acceptable to…
- Trial name
- Walk-BEST (NCT07621679)
- Testing
- Device: Heel2Toe[TM] sensor, Technology-assisted therapeutic walking program
- Where
- Canada
- Volunteers
- 28 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Prostate Cancer
Best Systemic Therapy or Best Systemic Therapy (BST) Plus Definitive Treatment (Radiation or Surgery)
The goal of this clinical research study is to learn if treatment with standard systemic therapy (androgen deprivation therapy or bilateral orchiectomy) in combination with surgery or radiation therapy is more effective at…
- Trial name
- NCT01751438
- Testing
- Best Systemic Therapy (BST), Best Systemic Therapy (BST) + Surgery or Radiation Therapy, Questionnaires
- Where
- 4 sites in United States, Canada
- Volunteers
- 180 people
- Sponsor
- M.D. Anderson Cancer Center
Oral Mucositis
A Trial Assessing Chemo Mouthpiece Device With Best Supportive Care for Symptoms of Chemotherapy-Induced Oral Mucositis
This study will compare the use of the Chemo MouthpieceTM device along with best supportive oral care to best supportive oral care alone to rate the effectiveness of Chemo MouthpieceTM in lessening symptoms associated with…
- Trial name
- NCT04595838
- Testing
- Chemo Mouthpiece, Best Supportive Care only
- Where
- 11 sites in United States
- Volunteers
- 176 people
- Sponsor
- Chemo Mouthpiece
Pancreatic Cancer
A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)
This is a study of a Multicenter, Randomized, Double-Blind, Phase III Study of IBI343 Monotherapy Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Participants with Claudin (CLDN) 18.2-Positive, Locally…
- Trial name
- NCT07066098
- Testing
- IBI343
- Where
- China
- Volunteers
- 201 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Carcinoma, Hepatocellular
Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma
The purpose of this phase III study is to determine whether Doxorubicin Transdrug (DT) is effective in the treatment of patients suffering from advanced Hepatocellular Carcinoma (HCC) after failure or intolerance to Sorafenib.
- Trial name
- ReLive (NCT01655693)
- Testing
- Doxorubicin 20 mg/m2, Doxorubicin 30 mg/m2, Best Standard of Care
- Where
- 70 sites in United States, Austria and 9 more
- Volunteers
- 397 people
- Sponsor
- Valerio Therapeutics
Fibromyalgia, Chronic Pain
A Positive Psychology Intervention for Fibromyalgia Patients Using ICT´s
This study is aimed to test the efficacy of a Positive Psychology Intervention (Best Possible Self, BPS) over optimism, future expectancies and positive affect at mid-term, in comparison to a control group, in fibromyalgia…
- Trial name
- BPS_FM (NCT02375061)
- Testing
- e-BPS, Daily Activities
- Where
- Spain
- Volunteers
- 80 people
- Sponsor
- Universitat Jaume I
Carotid Stenosis, Carotid Artery Diseases
Carotid Stenosis Management During COVID-19 Era - Pilot Study
Carotid endarterectomy (CEA) and carotid stenting (CAS) are often performed for subgroups of patients for whom procedural benefit has not been established in randomised trials and despite evidence of serious procedural risk.
- Conditions
- Carotid Stenosis, Carotid Artery Diseases, Carotid Atherosclerosis, Carotid Embolus
- Trial name
- CASCOM-Pilot (NCT04947046)
- Where
- Denmark
- Volunteers
- 120 people
- Sponsor
- Zealand University Hospital
Cardiovascular Diseases, Heart Diseases
Beta-Blocker Evaluation in Survival Trial (BEST)
To determine if addition of a beta-blocker to standard therapy in Class III and Class IV heart failure patients reduced total mortality.
- Conditions
- Cardiovascular Diseases, Heart Diseases, Heart Failure, Congestive, Heart Failure
- Trial name
- NCT00000560
- Testing
- adrenergic beta antagonists
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
COVID, Covid-19
Investigation of the Efficacy of CARDIO Softgels PLUS Best-standard-of-care in the Recovery of Patients With COVID-19
Corona virus disease 2019 (COVID-19) is caused by SARS-CoV-2, a plus-sense single-stranded RNA virus. After an incubation period, which typically lasts for 5-6 days, COVID-19 patients present with a mild illness that lasts for a…
- Trial name
- NCT04465513
- Testing
- Best Standard of Care + CARDIO, Best Standard of Care
- Where
- 8 sites in Brazil, Canada and 3 more
- Volunteers
- 14 people
- Sponsor
- Hofseth Biocare ASA